# US 2016/0251640 A1 · Compositions And Methods Of Nucleic Acid-Targeting Nucleic Acids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0251640 A1
- Document ID: US20160251640A1
- Status: Published application
- Kind: A1
- Application number: 15/159,776
- Filed: 2016-05-19
- Published: 2016-09-01
- Earliest claimed: 2013-03-14
- Assignees: Caribou Biosciences, Inc.
- Applicants: Caribou Biosciences, Inc.
- Inventors: Andrew Paul May; Rachel E. Haurwitz; Jennifer A. Doudna; James M. Berger; Matthew Merrill Carter; Paul Daniel Donohoue
- Web page: https://patentgrep.com/patent/US20160251640A1

## CPC

- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/6455: {Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/222: {Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes}
- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/52: Genes encoding for enzymes or proenzymes
- C12N 15/85: for animal cells
- C12N 15/90: Stable introduction of foreign DNA into chromosome
- C12N 15/902: {using homologous recombination}
- C12N 15/907: {in mammalian cells}
- C12Q 1/68: involving nucleic acids
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6818: involving interaction of two or more labels, e.g. resonant energy transfer
- C12Q 1/686: Polymerase chain reaction [PCR]
- C12Q 1/6869: Methods for sequencing
- C12Q 1/6874: involving nucleic acid arrays, e.g. sequencing by hybridisation
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2310/533: having a mismatch or nick in at least one of the strands
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

This disclosure provides for compositions and methods for the use of nucleic acid-targeting nucleic acids and complexes thereof. Genome engineering can refer to altering the genome by deleting, inserting, mutating, or substituting specific nucleic acid sequences. The altering can be gene or location specific. Genome engineering can use nucleases to cut a nucleic acid thereby generating a site for the alteration. Engineering of non-genomic nucleic acid is also contemplated.

## Claims

### Claim at position 1

1-26. (canceled)

### Claim 27

An engineered CRISPR Cas9 protein comprising:
a modification in a region of a CRISPR Cas9 protein corresponding to a region of amino acid residues 170-312 of a S. pyogenes-Cas9 protein (SEQ ID NO:8), wherein the modification comprises an insertion, deletion, or combination thereof.

### Claim 28 (depends on 27)

The engineered CRISPR Cas9 protein of claim 27, wherein the modification is made in identified regions of sequence similarity between the Cas9 protein and the S. pyogenes-Cas9 protein (SEQ ID NO:8).

### Claim 29 (depends on 27)

The engineered CRISPR Cas9 protein of claim 27, wherein the modification comprises a deletion.

### Claim 30 (depends on 27)

The engineered CRISPR Cas9 protein of claim 27, wherein the modification comprises a deletion of more than 5 amino acid residues.

### Claim 31 (depends on 27)

The engineered CRISPR Cas9 protein of claim 27, wherein the modification comprises a deletion of more than 100 amino acid residues.

### Claim 32 (depends on 27)

The engineered CRISPR Cas9 protein of claim 27, wherein the modification comprises a deletion and an insertion of a non-native amino acid sequence.

### Claim 33 (depends on 27)

The engineered CRISPR Cas9 protein of claim 27, wherein the modification comprises an insertion of a non-native amino acid sequence to form a fusion protein.

### Claim 34 (depends on 33)

The engineered CRISPR Cas9 protein of claim 33, wherein the non-native amino acid sequence comprises a functional domain.

### Claim 35 (depends on 27)

The engineered CRISPR Cas9 protein of claim 27, wherein the engineered CRISPR Cas9 protein is a fusion.

### Claim 36 (depends on 35)

The engineered CRISPR Cas9 protein of claim 35, wherein the engineered CRISPR Cas9 fusion comprises a detectable label.

### Claim 37 (depends on 35)

The engineered CRISPR Cas9 protein of claim 35, wherein the engineered CRISPR Cas9 fusion comprises the engineered CRISPR Cas9 protein and an endonuclease.

### Claim 38 (depends on 37)

The engineered CRISPR Cas9 protein of claim 37, wherein the endonuclease is FokI.

### Claim 39 (depends on 27)

The engineered CRISPR Cas9 protein of claim 27, wherein the engineered CRISPR Cas9 protein is enzymatically inactive.

### Claim 40 (depends on 27)

The engineered CRISPR Cas9 protein of claim 27, wherein the engineered CRISPR Cas9 protein is codon optimized for a host cell of interest.

### Claim 41 (depends on 40)

The engineered CRISPR Cas9 protein of claim 40, wherein the host cell of interest is a bacterial cell, an archaeal cell, a cell of a single-cell eukaryotic organism, a plant cell, an algal cell, a fungal cell, an animal cell, a cell from an invertebrate animal, a cell from a vertebrate animal, or a cell from a mammal.

### Claim 42 (depends on 41)

The engineered CRISPR Cas9 protein of claim 41, wherein the host cell is a human cell.

### Claim 43 (depends on 27)

A polynucleotide encoding the engineered CRISPR Cas9 protein of claim 27.

### Claim 44 (depends on 43)

The polynucleotide of claim 43, wherein the modification of the engineered CRISPR Cas9 protein is a deletion of more than 5 amino acid residues.

### Claim 45 (depends on 43)

The polynucleotide of claim 43, wherein the modification of the engineered CRISPR Cas9 protein is a deletion of more than 100 amino acid residues.

### Claim 46 (depends on 27)

A kit comprising:
the engineered CRISPR Cas9 protein of claim 27 or a polynucleotide encoding the engineered CRISPR Cas9 protein; and
a reagent.
